We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
- Authors
Davidson, Karina W.; Barry, Michael J.; Mangione, Carol M.; Cabana, Michael; Caughey, Aaron B.; Davis, Esa M.; Donahue, Katrina E.; Doubeni, Chyke A.; Kubik, Martha; Li, Li; Ogedegbe, Gbenga; Pbert, Lori; Silverstein, Michael; Simon, Melissa A.; Stevermer, James; Tseng, Chien-Wen; Wong, John B.
- Abstract
<bold>Importance: </bold>Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality. Preeclampsia also accounts for 6% of preterm births and 19% of medically indicated preterm births in the US. There are racial and ethnic disparities in the prevalence of and mortality from preeclampsia. Non-Hispanic Black women are at greater risk for developing preeclampsia than other women and experience higher rates of maternal and infant morbidity and perinatal mortality.<bold>Objective: </bold>To update its 2014 recommendation, the USPSTF commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia.<bold>Population: </bold>Pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin.<bold>Evidence Assessment: </bold>The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia.<bold>Recommendation: </bold>The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons who are at high risk for preeclampsia. (B recommendation).
- Subjects
PREECLAMPSIA prevention; RESEARCH; PREMATURE infants; NONSTEROIDAL anti-inflammatory agents; RESEARCH methodology; SYSTEMATIC reviews; MEDICAL cooperation; EVALUATION research; PERINATAL death; RISK assessment; PREECLAMPSIA; COMPARATIVE studies; ASPIRIN; SMALL for gestational age
- Publication
JAMA: Journal of the American Medical Association, 2021, Vol 326, Issue 12, p1186
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2021.14781